Ghaziabad Online

Refractory Multiple Myeloma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Refractory Multiple Myeloma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
19:16 2023
Refractory Multiple Myeloma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s ‘Refractory Multiple Myeloma Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline refractory multiple myeloma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the refractory multiple myeloma pipeline domain.

 

In the ‘Refractory Multiple Myeloma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, ‘Refractory Multiple Myeloma clinical trial studies, ‘Refractory Multiple Myeloma NDA approvals (if any), and product development activities comprising the technology, Refractory Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

  • DelveInsight’s refractory multiple myeloma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for refractory multiple myeloma treatment. 

 

  • Key refractory multiple myeloma companies such as NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.

 

  • Promising refractory multiple myeloma pipeline therapies in various stages of development include NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797,  and others.

 

  • The Refractory Multiple Myeloma Companies and academics are working to assess challenges and seek opportunities that could influence Refractory Multiple Myeloma R&D. The Refractory Multiple Myeloma pipeline therapies under development are focused on novel approaches to treat/improve Refractory Multiple Myeloma.

 

To explore more information on the latest breakthroughs in the Refractory Multiple Myeloma treatment landscape of the report, click here @ Refractory Multiple Myeloma Pipeline Outlook

 

Recent Developmental Activities in the Refractory Multiple Myeloma Treatment Landscape

  • In August 2022, Ipsen announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at the deal close.

 

Refractory Multiple Myeloma Overview

Multiple myeloma is a type of cancer that begins in a type of white blood cell known as a plasma cell. It’s rare, accounting for less than 2% of all plasma cell tumors, but it’s the most common type, according to the CDC. Although the survival rate of multiple myeloma has improved in recent years, initial refractory multiple myeloma treatment is still ineffective in the vast majority of cases. If myeloma is resistant to treatment or becomes resistant during treatment, it is said to be refractory. The refractory multiple myeloma symptoms are the same as those of multiple myeloma. These refractory multiple myeloma symptoms either persist or return after treatment. The most common refractory multiple myeloma symptom is bone pain.

 

Request a sample and discover the recent advances in Refractory Multiple Myeloma Ongoing Clinical Trial Analysis and Medications, click here @ Refractory Multiple Myeloma Treatment Landscape

 

Refractory Multiple Myeloma Emerging Drugs Profile

 

NEXI 002: NexImmune

NEXI-002 is an endogenous (non-genetically engineered) cellular therapy and includes populations of primed antigen specific CD8+ cells directed at five specific multiple myeloma antigen targets.  Generating T cells against multiple tumor targets minimizes the potential for tumor escape.  In addition, NEXI-002 contains T cell subtypes that are predominantly memory phenotypes, with the majority being characterized as stem cell memory and central memory T cells.  T cell products that contain high proportions of memory cells, particularly central memory and stem cell memory, have been associated with potent anti-tumor activity, long-term T cell persistence and durable anti-tumor response. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Multiple Myeloma.

 

AMG-701: Amgen

Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of Relapsed/Refractory Multiple Myeloma.

 

ABBV 453: AbbVie

ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Multiple Myeloma.

 

Refractory Multiple Myeloma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Refractory Multiple Myeloma. The companies which have their Refractory Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase I/II include, NexImmune.

 

For further information, refer to the detailed Refractory Multiple Myeloma Unmet Needs, Refractory Multiple Myeloma Market Drivers, and Market Barriers, click here for Refractory Multiple Myeloma Ongoing Clinical Trial Analysis

 

Scope of the Refractory Multiple Myeloma Pipeline Report 

 

  • Coverage: Global 

 

  • Key Refractory Multiple Myeloma Companies: NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.

 

  • Key Refractory Multiple Myeloma Pipeline Therapies: NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797,  and others.

 

  • Refractory Multiple Myeloma Pipeline Segmentation: Phases, Product Type, Mechanism of action, Route of administration, Molecule Type

 

Dive deep into rich insights for drugs for Refractory Multiple Myeloma Market Drivers and Refractory Multiple Myeloma Market Barriers, click here @ Refractory Multiple Myeloma Unmet Needs and Analyst Views

 

Table of Contents

  1. Introduction
  2. Refractory Multiple Myeloma Executive Summary
  3. Refractory Multiple Myeloma Overview
  4. Refractory Multiple Myeloma Pipeline Therapeutics
  5. Refractory Multiple Myeloma Pipeline Therapeutic Assessment
  6. Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase I/II)
  9. NEXI 002: NexImmune
  10. Early Stage Products (Phase I)
  11. ABBV 453: AbbVie
  12. Preclinical and Discovery Stage Products
  13. Inactive Products
  14. Refractory Multiple Myeloma Key Companies
  15. Refractory Multiple Myeloma Key Products
  16. Refractory Multiple Myeloma- Unmet Needs
  17. Refractory Multiple Myeloma- Market Drivers and Barriers
  18. Refractory Multiple Myeloma- Future Perspectives and Conclusion
  19. Refractory Multiple Myeloma Analyst Views
  20. Refractory Multiple Myeloma Key Companies
  21. Appendix

 

Got Queries? Find out the related information on Refractory Multiple Myeloma Mergers and acquisitions, Refractory Multiple Myeloma licensing activities @ Refractory Multiple Myeloma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services